Investors

Investors

影俊vnp官网

Horizon is a biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.  We believe science and compassion must work together to transform lives. 
 
Horizon's global headquarters is in Dublin, Ireland.  The Company also has offices in Lake Forest, Ill.; Chicago, Ill.; Brisbane, Calif.; Novato, Calif.; Washington, D.C. and Mannheim, Germany.

影俊vnp官网

Aug 5, 2023
8:00 AM EDT

影俊vnp官网

Add to Outlook
Add to Google Calendar

影俊vnp官网

Volume:

Refresh Quote

影俊vnp官网

Date Title
07/31/20
Summary ToggleNew Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
赛·风3安卓下载
Summary ToggleTarget Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout
07/13/20
Summary ToggleHorizon Therapeutics plc to Release Second-Quarter 2023 Financial Results and Host Webcast on Aug. 5, 2023
TEPEZZA® Presentation
ESG Overview (2023 Proxy)
赛 风破解版 下载
Investor Presentation
赛 风破解版 下载

影俊vnp官网

Investor Contacts Tina Ventura
Senior Vice President,
Investor Relations
Investor-relations@horizontherapeutics.com

Ruth Venning
Executive Director,
Investor Relations
Investor-relations@horizontherapeutics.com
賽风安卓版百度云 Geoff Curtis
Executive Vice President,
Corporate Affairs & Chief
Communications Officer
media@horizontherapeutics.com
+1 888 506-2562
Ireland Media Contact Ray Gordon
Gordon MRM
ray@gordonmrm.ie
+353 (87) 2417373
Shareholder Tools

影俊vnp官网

  • Email Alerts Subscription
  • RSS News Feeds
  • Snapshot
  • Print
  • 老大加速器  能vpn的加速器  pigcha下载  AURORA极光官网  暴雪vp破解版  蓝灯梯子加速器  快读VPN